Form 4: Dyne Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
A Dyne Therapeutics executive sold shares to cover tax obligations related to vesting restricted stock units.
Summary
- Richard Scalzo, SVP, Head of Finance & Admin at Dyne Therapeutics, sold 1,455 shares of common stock on December 11, 2024.
- The sale was to satisfy tax withholding obligations related to the vesting of restricted stock units granted in 2021 and 2022.
- The shares were sold at a weighted average price of $28.12.
- The sale was not a discretionary trade but an automatic sale as part of a restricted stock unit agreement.
- The shares were sold in multiple transactions at prices ranging from $27.76 to $28.71.
- The executive also holds 119,688 unvested restricted stock units.
Sentiment
Score: 5
Explanation: The document describes a routine transaction related to executive compensation and tax obligations. It does not indicate any positive or negative sentiment towards the company's performance or future outlook.
Industry Context
Executive stock sales are a common occurrence, especially when related to vesting of stock options or restricted stock units. This is a routine transaction and does not necessarily indicate a change in the company's outlook.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a standard practice across the industry.
- Many biotech companies use stock-based compensation, and executives often sell shares to cover taxes when these units vest.
- This type of transaction is similar to what is seen at companies like BioMarin Pharmaceutical and Sarepta Therapeutics, where executives regularly sell shares for tax purposes.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on the stock price, but it is not expected to have a significant impact on shareholders.
- The transaction is a normal part of executive compensation and does not indicate any change in the company's operations or strategy.
Key Dates
| Date | Description |
|---|---|
| 2021-12-10 | Date of one of the restricted stock unit grants. |
| 2022-12-09 | Date of one of the restricted stock unit grants. |
| 2024-12-11 | Date of the stock sale and filing of the Form 4. |
Keywords
Dyne Therapeutics, stock sale, executive, restricted stock units, tax obligations, Richard Scalzo
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.